Replimune Group, Inc. (REPL) has announced the pricing for its public offering of 6.923 million common shares at a price of $13.00 per share, with the transaction anticipated to close on November 27, 2024.
The company has also set the terms for a public offering of pre-funded warrants, which allow for the purchase of 3.846 million common shares at $12.9999 per warrant. This price reflects the public offering price per common stock share, minus the $0.0001 exercise price for each pre-funded warrant.
Additionally, Replimune has granted the underwriter a 30-day option to acquire up to an extra 1.615 million common shares.
The company anticipates gross proceeds from the offering to be approximately $140 million before deducting expenses.
Leerink Partners is serving as the sole bookrunning manager for this offering.
